Glaxosmithkline Pharmaceuticals Ltd
Glaxosmithkline Pharmaceuticals Ltd Share Price Today: Live Updates & Key Insights
Get insights on Glaxosmithkline Pharmaceuticals Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Glaxosmithkline Pharmaceuticals Ltd Share Price Chart
Glaxosmithkline Pharmaceuticals Ltd Fundamentals
Traded Volume: 72,263
Market Cap(Cr): 42,316
Avg Traded Price 2503.33
1 Year return 5.41%
Upper Circuit 2,523.4
Lower Circuit 2,488
P/E TTM 44.00
P/B Ratio 56.00
Traded Value(Cr) 1805.06
EPS TTM 56.388
Book value 56.388
Dividend 2.00%
Glaxosmithkline Pharmaceuticals Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Glaxosmithkline Pharmaceuticals Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Glaxosmithkline Pharmaceuticals Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +0.14%
1M -9.03%
3M -10.19%
1Y +5.41%
YTD +12.41%
Glaxosmithkline Pharmaceuticals Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Glaxosmithkline Pharmaceuticals Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 31608.00
Day Before Yesterday 53349.00
1W Avg 75854.60
1M Avg 87395.76
3M Avg 83451.89
Glaxosmithkline Pharmaceuticals Ltd Technical Details
Glaxosmithkline Pharmaceuticals Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 2483
Support 2 2468
Support 3 2447
Pivot Point : 2503
Resistance 1 2518
Resistance 2 2539
Resistance 3 2554
Glaxosmithkline Pharmaceuticals Ltd Corporate Actions
Glaxosmithkline Pharmaceuticals Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Glaxosmithkline Pharmaceuticals Ltd’s capital allocation strategies.
All
Ex-Date 30-May-2025 Type D Description 42.00/share@420.00% Record Date 30-May-2025 Ratio 420.00
Ex-Date 07-Nov-2024 Type D Description 12.00/share@120.00% Record Date 07-Nov-2024 Ratio 120.00
Ex-Date 31-May-2024 Type D Description 32.00/share@320.00% Record Date 31-May-2024 Ratio 320.00
Ex-Date 30-Jun-2023 Type D Description 32.00/share@320.00% Record Date 30-Jun-2023 Ratio 320.00
Ex-Date 07-Jul-2022 Type D Description 60.00/share@600.00% Record Date 08-Jul-2022 Ratio 600.00
Ex-Date 07-Jul-2022 Type D Description 30.00/share@300.00% Record Date 08-Jul-2022 Ratio 300.00
Ex-Date 19-Jul-2021 Type D Description 30.00/share@300.00% Record Date 20-Jul-2021 Ratio 300.00
Ex-Date 17-Jul-2020 Type D Description 20.00/share@200.00% Record Date 20-Jul-2020 Ratio 200.00
Ex-Date 17-Jul-2020 Type D Description 20.00/share@200.00% Record Date 20-Jul-2020 Ratio 200.00
Ex-Date 11-Jul-2019 Type D Description 20.00/share@200.00% Record Date - Ratio 200.00
Ex-Date 11-Sep-2018 Type B Description share@1:1 Record Date 13-Sep-2018 Ratio 1:1
Ex-Date 13-Jul-2018 Type D Description 35.00/share@350.00% Record Date - Ratio 350.00
Ex-Date 14-Jul-2017 Type D Description 30.00/share@300.00% Record Date - Ratio 300.00
Ex-Date 15-Jul-2016 Type D Description 50.00/share@500.00% Record Date - Ratio 500.00
Ex-Date 23-Jul-2015 Type D Description 62.50/share@625.00% Record Date - Ratio 625.00
Ex-Date 03-Apr-2014 Type D Description 50.00/share@500.00% Record Date - Ratio 500.00
Ex-Date 04-Apr-2013 Type D Description 50.00/share@500.00% Record Date - Ratio 500.00
Ex-Date 29-Mar-2012 Type D Description 45.00/share@450.00% Record Date - Ratio 450.00
Ex-Date 14-Mar-2011 Type D Description 40.00/share@400.00% Record Date - Ratio 400.00
Ex-Date 10-Mar-2010 Type D Description 30.00/share@300.00% Record Date - Ratio 300.00
Ex-Date 18-Mar-2009 Type D Description 18.00/share@180.00% Record Date - Ratio 180.00
Ex-Date 18-Mar-2009 Type D Description 22.00/share@220.00% Record Date - Ratio 220.00
Ex-Date 02-Apr-2008 Type D Description 18.00/share@180.00% Record Date - Ratio 180.00
Ex-Date 02-Apr-2008 Type D Description 18.00/share@180.00% Record Date - Ratio 180.00
Ex-Date 14-Mar-2007 Type D Description 14.00/share@140.00% Record Date - Ratio 140.00
Ex-Date 14-Mar-2007 Type D Description 17.00/share@170.00% Record Date - Ratio 170.00
Dividends
Announcement Date 30-May-2025 Ex Dividend Date 30-May-2025 Dividend(%) 420
Announcement Date 07-Nov-2024 Ex Dividend Date 07-Nov-2024 Dividend(%) 120
Announcement Date 31-May-2024 Ex Dividend Date 31-May-2024 Dividend(%) 320
Announcement Date 30-Jun-2023 Ex Dividend Date 30-Jun-2023 Dividend(%) 320
Announcement Date 07-Jul-2022 Ex Dividend Date 07-Jul-2022 Dividend(%) 600
Announcement Date 07-Jul-2022 Ex Dividend Date 07-Jul-2022 Dividend(%) 300
Announcement Date 19-Jul-2021 Ex Dividend Date 19-Jul-2021 Dividend(%) 300
Announcement Date 17-Jul-2020 Ex Dividend Date 17-Jul-2020 Dividend(%) 200
Announcement Date 17-Jul-2020 Ex Dividend Date 17-Jul-2020 Dividend(%) 200
Announcement Date 11-Jul-2019 Ex Dividend Date 11-Jul-2019 Dividend(%) 200
Announcement Date 13-Jul-2018 Ex Dividend Date 13-Jul-2018 Dividend(%) 350
Announcement Date 14-Jul-2017 Ex Dividend Date 14-Jul-2017 Dividend(%) 300
Announcement Date 15-Jul-2016 Ex Dividend Date 15-Jul-2016 Dividend(%) 500
Announcement Date 23-Jul-2015 Ex Dividend Date 23-Jul-2015 Dividend(%) 625
Announcement Date 03-Apr-2014 Ex Dividend Date 03-Apr-2014 Dividend(%) 500
Announcement Date 04-Apr-2013 Ex Dividend Date 04-Apr-2013 Dividend(%) 500
Announcement Date 29-Mar-2012 Ex Dividend Date 29-Mar-2012 Dividend(%) 450
Announcement Date 14-Mar-2011 Ex Dividend Date 14-Mar-2011 Dividend(%) 400
Announcement Date 10-Mar-2010 Ex Dividend Date 10-Mar-2010 Dividend(%) 300
Announcement Date 18-Mar-2009 Ex Dividend Date 18-Mar-2009 Dividend(%) 180
Announcement Date 18-Mar-2009 Ex Dividend Date 18-Mar-2009 Dividend(%) 220
Announcement Date 02-Apr-2008 Ex Dividend Date 02-Apr-2008 Dividend(%) 180
Announcement Date 02-Apr-2008 Ex Dividend Date 02-Apr-2008 Dividend(%) 180
Announcement Date 14-Mar-2007 Ex Dividend Date 14-Mar-2007 Dividend(%) 140
Announcement Date 14-Mar-2007 Ex Dividend Date 14-Mar-2007 Dividend(%) 170
Bonus
Record Date 13-Sep-2018 Ex-Bonus Date 11-Sep-2018 Ratio 1:1
Splits
No Split has been declared by GLAXO
Others
Rights No Rights has been declared by GLAXO
Glaxosmithkline Pharmaceuticals Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Glaxosmithkline Pharmaceuticals Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Glaxosmithkline Pharmaceuticals Ltd's relative performance and valuation against major competitors.
Stock Name Abbott India Ltd ₹29575.00 (-0.03%) M. Cap (Cr) 628.47 1 Yr Return (%) +9.07% P/E (TTM) 41.65 PB Ratio 14.85
Stock Name Laurus Labs Ltd ₹978.20 (-0.90%) M. Cap (Cr) 528.06 1 Yr Return (%) +99.98% P/E (TTM) 77.21 PB Ratio 11.81
Stock Name Glenmark Pharmaceuticals Ltd ₹1844.20 (-1.80%) M. Cap (Cr) 520.43 1 Yr Return (%) +25.76% P/E (TTM) 51.54 PB Ratio 5.88
Stock Name Glaxosmithkline Pharmaceuticals Ltd ₹2497.90 (-0.44%) M. Cap (Cr) 423.16 1 Yr Return (%) +5.41% P/E (TTM) 44.30 PB Ratio 21.69
Stock Name Ipca Laboratories Ltd ₹1444.00 (+0.40%) M. Cap (Cr) 366.35 1 Yr Return (%) -8.23% P/E (TTM) 44.05 PB Ratio 5.27
Stock Name Anthem Biosciences Ltd ₹635.10 (-1.91%) M. Cap (Cr) 356.68 1 Yr Return (%) NaN% P/E (TTM) 69.10 PB Ratio 14.80
Stock Name Ajanta Pharma Ltd ₹2485.70 (-1.00%) M. Cap (Cr) 310.55 1 Yr Return (%) -15.61% P/E (TTM) 31.89 PB Ratio 8.44
Glaxosmithkline Pharmaceuticals Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Glaxosmithkline Pharmaceuticals Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 1280.03 Mar 2024 578.94 Mar 2023 487.94 Mar 2022 819.79 Mar 2021 594.87
PARTICULARS Investing Activities Mar 2025 -36.53 Mar 2024 14.97 Mar 2023 805.19 Mar 2022 -419.66 Mar 2021 407.57
PARTICULARS Financing Activities Mar 2025 -769.42 Mar 2024 -561.50 Mar 2023 -1544.18 Mar 2022 -524.24 Mar 2021 -695.56
PARTICULARS Net Cash Flow Mar 2025 474.07 Mar 2024 32.41 Mar 2023 -251.05 Mar 2022 -124.11 Mar 2021 306.87
Glaxosmithkline Pharmaceuticals Ltd Shareholding Pattern
This shows the ownership breakdown of Glaxosmithkline Pharmaceuticals Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 75.0%
Public 12.0%
Other Institutions 3.0%
FII 5.0%
Mutual Funds 5.0%
About Glaxosmithkline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924. The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India. The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.The Company's portfolio includes General Medicines, Vaccines and Specialty medicines that help prevent and treat disease. Their prescription medicines range across therapeutic areas, such as Anti-Infectives, Dermatology, Gynaecology, Diabetes, Oncology, Cardiovascular Disease and Respiratory Diseases. They also offer a range of vaccines, for the prevention of Hepatitis A, Hepatitis B, Invasive Disease caused by H, Influenza, Chickenpox, Diphtheria, Pertussis, Tetanus, Rotavirus, Cervical Cancer and Others. They have two manufacturing units in India, located at Nashik and Thane. Also, they have a clinical development centre in Bangalore. During year 1956, the Company began primary production of vaccines at Worli. In the year 1960, the company started manufacturing Infant foods at milk drying plant at Aligarh. They also opened manufacturing facility for pharmaceuticals in Mumbai. In 1961, the Company started manufacturing Vitamin A and Betamethasone at new plant at Thane using imported raw materials. The Company registered as a limited company in the year 1968. Also, they introduced the Animal health products. In the year 1971, the company built the Research & development laboratory at Thane. Also, they relocated the SmithKline & French plant from Mumbai to Bangalore. In the year 1983, they commissioned the Nashik factory. SmithKline & Beecham became a public limited company under the new name of Eskayef Ltd in the year 1984 and one new Plant was set up in Mysore for manufacture of bulk drugs. In the year 1985, the company's second basic drugs factory was inaugurated at Ankleshwar, Gujarat. In the year 1986, the company launched joint venture projects Vegepro Foods and Feeds Ltd and K G Gluco Biols. In the year 1988, the company commenced the production of bulk drug Ranitidine at Ankleshwar. Also, they started a joint venture project with Hindustan Foods Ltd for the manufacture of extruded foods at Usgao, Goa. In the year 1989, the company commenced their Zinetac production at Nashik. In the year 1990, the production of the bulk drug, cephalexin was commenced at Ankleshwar and the salbutamol inhalers at Nashik. Glaxo rated amongst the first five of India's most respected companies (4th place), in a survey by Businessworld magazine. An agreement was signed with the Council of Scientific and Industrial Research (CSIR) during 1991. In the year 1992, the company sold their trade investments in Vegepro and Feeds Ltd. In the year 1993, they sold their investment in Hindustan Foods Ltd and Dempo Dairy Industries Ltd. Cetzine, a second-generation anti-histamine and research product of UCB Pharma (Belgium) was launched under a co-marketing agreement. In the same year Glaxo received recognition from the Ministry of Commerce as an export house. In the year 1994, the company sold their Family Products Division to H J Heinz for a sum of Rs 210 crore. The Mysore plant received ISO 9002 certification and the new Iodex plant was inaugurated in Bangalore. In the year 1995, they inaugurated the government approved state-of-the-art Pharmacy Research & Development Centre (PR&D) at Thane to cater to the unmet medical needs and to exploit local commercial opportunities.In the year 1998, the company acquired Biddle Sawyer Group of Companies, which was struggled in the year before. In the year 2000, Agrivet Farm Care (AFC) tied up with Merial, the world's largest Animal Health Company, to market poultry vaccines. The company ranked 6th in 'Business Today' - Stern Stewart & Co. listing of India's best Wealth Creator Companies and also the launched Seretide for Asthma. The merger of SmithKline Beecham Pharmaceuticals (India) Ltd into Glaxo India Limited was completed. Businessworld and the Indian Market Research Bureau (IMRB) named GlaxoSmithKline as India's most respected Pharmaceutical Company in a survey in the year 2003. During the year, the company launched Cetzine (Cetirizine; anti-histamine), Zimig (terbinafine; anti-infective), CCM (calcium citrate maleate; nutritional), Cobadex CZS (multivitamin with trace elements).In the year 2004, the company launched Priorix (measles, mumps, rubella vaccine). In the year 2005, the company launched oral contraceptives: Elogen (desogestrel and ethinylestradiol) and Zerogen (progesterone only pill). They entered into the diabetes therapeutic segment with the launch of Windia (rosiglitazone) and Windamet (rosiglitazone and metformin). In the year 2006, the company made an in-licensing alliance with Eisai Pharmaceuticals, Japan and launched Parit (rabeprazole; gastrointestinal therapy area). Also, GlaxoSmithKline divested their Agrivet Farm Care (AFC) animal health business. In the year 2007, the company launched Carzec (carvedilol) and Zemetril (cefprozil). In March 2007, the company opened new Medicinal Chemistry Laboratory at their R&D facility in Singapore. Also, they divested their other peripheral business of fine chemicals with consideration of Rs 240 crore on slump sale basis to Thermo Electron LLS India Private Ltd. In the year 2008, the company increased the installed capacity of Tablets and Capsules from 6750 million nos to 6950 million nos. They increased the production capacity of Solids including Powders and Ointments from 1550 tonnes to 2225 tonnes. In January 2008, the company launched two of their new innovative Diphtheria, Tetanus and acellular Pertussis (DTP) vaccines, such as Boostrix and Infanrix. Also the company in well positioned to launch the breast cancer drug, Tykerb and the rotavirus vaccine, Rotarix during the year. Also, they rolled out three new Business Partnering initiatives during the year. In the year 2009, the company launched new products, namely Benitec A (Olmesatan in combination with Amilodipine) in Cardiology, Dermocalm (Calamine lotion) in Dermatology, Ventorlin CFC free inhaler (Salbutamol) in Respiratory and Esblanem (Meropenem) in Antibiotic segments. Their Nashik site commenced manufacture and supply of Albendazole tablets to WHO for the Lymphatic Filriasis eradication programme.In the year 2010, the company increased the installed capacity of Solids including Powders and Ointments from 2225 tonnes to 2600 tonnes. They launched some new products namely, Mycamine inj (Micafungin) in-licensed from Astellas and Parit D capsules (Rabeprazole in combination with Domperidone) in-licensed from Eisai. Cefspan (Cefixime - oral antibiotic) was relaunched with good success. Other branded generics launched during the year were Modvate 3 cream (Beclomethasone in combination with Clotrimazole and Neomycin) and Modvate AF cream (Beclomethasone in combination witr Clotrimazole) in Dermatology. Formulations of Atorvastatin and Rosuvastatin tablets were launchec in Cardiology under the brand names 'Lilo' and 'Rosutec' respectively. The combination of Paracetamol with Tramadol was launched under the brand name 'Calpol T'. In the year 2011, the company foray into branded generics market. Zobactin is ranked as the No. 2 brand (Dec MAT 2011, H.S.A) in a market which has more than 56 brands of Piperacillin+Tazobactum. In the Meropenem market, Esblanem is ranked at 6th position (Dec MAT 2011, H.S.A). After the successful launch of Tykerb in 2008, they expanded their presence further by introducing two new segments, Kidney Cancer and Hematology with launch of Votrient and Revolade.In 2012, the company Introduces Metered Dose Inhaler with dose counter. On 30 September 2015, the company announced the completion of its transaction with Novartis Healthcare Pvt. Ltd. (Novartis India) whereby the company has acquired Novartis' vaccines business and divested its marketed oncology portfolio to Novartis India. This follows a global transaction between GlaxoSmithKline plc, UK (GSK) and Novartis AG, Switzerland (Novartis) which was completed in March 2015 on the same basis. The acquisition of the vaccines business of Novartis provides GSK with an exciting opportunity to build an even stronger, sustainable global vaccines business. The transaction will enhance GSK's vaccines portfolio and bring together its expertise in virology, bacterial infection and technological platforms to deliver a reliable supply of high quality vaccines.During the quarter ended 30 September 2016, the company successfully launched Priorix-Tetra, a combined measles, mumps, rubella and varicella vaccine. During the quarter ended 31 December 2016, the company successfully launched EnteroPlus, a probiotic food supplement. The company also restored the manufacturing of a key brand, Neosporin, an antibiotic used to treat minor wounds.During the quarter ended 30 September 2017, the company announced its intention to dispose of its surplus land at Thane in Maharashtra to Oberoi Realty for Rs 555 crore subject to receipt of all regulatory and statutory approvals, as well as various conditions as agreed with the purchaser. During the quarter ended 31 December 2017, the company received the money in advance towards disposal of Thane land. During the quarter ended 31 March 2018, the company successfully launched Biopatch, a hydrophilic wound dressing that is used to cover a wound caused by the use of percutaneous medical devices. Biopatch is recommended in skin sterilization protocol to reduce the incidence of CRBSI. Patients at risk of CRBSI are the ones in ICUs, those receiving chemotherapy and patients undergoing dialysis through catheters.The Company has allotted fully paid up equity shares of Rs 10 each during the quarter ended 30th September 2018, pursuant to a bonus issue in ratio 1:1, as approved by the members through postal ballot. 8,47,03,017 Bonus shares have been issued by capitalization of profits transferred from general reserve.The manufacturing facility for Eltroxin has commenced operation since 2019. In December 2019, the Company launched Menveo a Quadrivalent Meningococcal Conjugate Vaccine.During FY2020,the company spent Rs 41 crore as capital expenditure, towards renovation of its corporate office into a modern workplace. In September 2020, the Company launched tetravalent influenza flu vaccine, Fluarix Tetra to help combat influenza.In June, 2021 Company launched the 'Nucala', first anti-IL5 drug, auto-injector device in India. It launched Trelegy Ellipta, the country's first single inhaler triple therapy (SITT) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) patients. It launched Augmentin ES deploying technology in reaching out to key specialists in ear, nose and throat (ENT) and Paediatrics practice. Calpol+ with OPTIZORB formulation was launched in March 2023. The Company launched Shingrix, an adult vaccination for the prevention of Herpes Zoster and post-herpetic neuralgia (PHN) in 2024.In 2025, Company has launched two new line extensions for Eltroxin-125 mcg & 37.5 mcg- and introduced innovative protective packaging with scavenger technology, ensuring consistent dosing & stability. Company has forayed into newer segments like emollients with Physiogel, which is now the fourth most prescribed emollient brand among Dermatologists. In FY2024-25, Company introduced T-Bact ointment 15g in a new Lami pack format and Becadexamin capsules were launched in a 60s HDPE pack format to improve efficiency.
Independent Director
D Sundaram
Registered office GSK House, Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030
FAX :91-022-24959595
Background
Incorporation Year 1924
Face Value ₹10.00
Market Lot 1
FAQs on Glaxosmithkline Pharmaceuticals Ltd
How to buy Glaxosmithkline Pharmaceuticals Ltd shares on NSE?
To buy Glaxosmithkline Pharmaceuticals Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Glaxosmithkline Pharmaceuticals Ltd share price today?
The Glaxosmithkline Pharmaceuticals Ltd share price on NSE is ₹2497.90 today.
What is the market cap of Glaxosmithkline Pharmaceuticals Ltd on NSE?
The company has a market capitalization of ₹42315.93.
What is the PE & PB ratio of Glaxosmithkline Pharmaceuticals Ltd?
PE is 44 and PB is 56.
What is the 52 Week High and Low of Glaxosmithkline Pharmaceuticals Ltd shares?
Glaxosmithkline Pharmaceuticals Ltd stock price high: ₹3515.70 Glaxosmithkline Pharmaceuticals Ltd stock price low: ₹1921.
What is the correct way to invest in Glaxosmith?
The correct way to invest in GlaxoSmithKline Pharmaceuticals is to buy the shares of the company through a reputed broker like Motilal Oswal. You can sign up with the broker online and open a dreamt and trading account first. Then, you can place an order to buy the company stock through the broker and invest in the company.
How can I sell Glaxosmith Pharma shares?
To sell GlaxoSmithKline Pharmaceutical shares you must be signed up with a broker like Motilal Oswal. Shares must be held in a demat account to be sold. You also need to have a trading account linked to your demat account. Once you place a sell request with your broker, your shares are sold and the proceeds are credited to your bank account linked with your demat and trading accounts.
What is the ROI of Glaxosmith Pharma shares?
The current year ROI (YTD 17 April 2023) of GlaxoSmithKline Pharmaceutical shares is -3.81%.
Can I buy Glaxosmith Pharma shares now?
You can buy the shares of GlaxoSmithKline Pharmaceuticals now or at any time through a reputed broker like Motilal Oswal. All you require is a demat account linked with a trading account. These two accounts are connected to your bank account and you can easily place a buy order with your broker to buy the shares you want.
What is the trending volume of Glaxosmith Pharma shares?
The trading volume of GlaxoSmithKline Pharmaceutical shares is 53,700 (17 April 2023).